Explore the Agenda

8:15 am Check-In & Morning Coffee

8:50 am Chair’s Opening Remarks

Designing Ethical, Defensible, & Actionable Data Strategies in Expanded Access

9:00 am Turning EAP Data into Action: Applying Insights to Regulatory & Access Strategy

Associate Director, Gilead Sciences
  • Differentiating how EAP data complements clinical trial outcomes
  • Understanding how EAP data is being used to support regulatory dialogue and submissions
  • Integrating real-world insights into broader evidence-generation and access planning
  • Demonstrating how RWD collected through EAPs is used to inform pricing, reimbursement decisions, and negotiations with health authorities, backed by realworld case studies

9:30 am Roundtable: What Data Can We Ethically & Safely Collect in Expanded Access?

  • Clarifying what constitutes acceptable insight generation versus study-like data collection
  • Reducing internal risk aversion by aligning on intent, transparency, and patient benefit
  • Defining ethical, regulatory, and reputational guardrails for EAP data collection

10:00 am Session Reserved for MedaSystems

Right click on the image to save it to your computer.

10:30 am Morning Break & Networking

Building Sustainable Access: Provider, Patient, and System-Level Solutions

11:15 am Redefining Expanded Access in ALS: Lessons from a Government- Funded National Program

Vice President - Medical Affairs, Clene Nanomedicine
  • Balancing compassionate access with scientific rigor in a federally funded ALS Expanded Access Program
  • Advancing health equity by prioritizing access for underserved and remote ALS patient populations
  • Generating real-world evidence from expanded access data to support regulatory and development decisions

11:45 am Empowering Oncology Health Care Providers to Improve Expanded Access Enrollment

Global Oncology Medical Strategy Manager, Daiichi Sankyo
Global Oncology Medical Affairs & Clinical Trial Management, Daiichi Sankyo
  • New insights into knowledge gaps among U.S. oncology health care providers related to Expanded Access Programs
  • Key patient enrollment and operational barriers encountered by providers and care teams
  • Interactive discussion on how industry can better support oncology health care providers through education, tools, and process improvements
  • Practical strategies to help providers more efficiently connect eligible patients to Expanded Access treatment options

12:30 pm Patient-Led Models for Scaling Access Across High and Low-Income Countries

Chief Executive Officer, CML BUSTER Foundation
Co-Founder & Chief Financial Officer, CML BUSTER Foundation
  • Reaching underserved populations when traditional access mechanisms fail
  • Managing chronic treatment access for thousands of patients across diverse health systems
  • Coordinating pharma, clinicians, and patient organizations to reduce friction and delay
  • Embedding access strategy early to support long-term equity and sustainability

1:00 pm Lunch & Networking

2:00 pm Session Reserved for Inceptua

Right click on the image to save it to your computer.

Launching Expanded Access with Limited Teams, Budget & Infrastructure

2:30 pm Building Credible EAPs as a Team of One

Associate Director, Ascendis Pharma A/S
  • Establishing fit-for-purpose policies and documentation without large pharma systems
  • Educating internal stakeholders on how EAPs differ from clinical trials
  • Balancing strategic planning with day-to-day operational execution
  • Building internal confidence and decision-making credibility without a dedicated team

3:00 pm Roundtable: Securing Buy-In, Funding, & Guardrails in Risk-Averse Organizations

Director - Rare Disease, Medical Affairs, Biogen
  • Navigating leadership concerns around regulatory, reputational, and approval risk
  • Making the business and ethical case for EAP investment pre-approval
  • Designing guardrails that protect programs without stalling access

Avoiding Patient Disruption as Expanded Access Ends & Commercial Begins

3:30 pm FDA approval: Now What?

Director, Market Access Strategy & Marketing, National Accounts & Patient Services, Stealth BioTherapeutics
  • Defining strategies for EAP patients that are now ready to be transferred to commercial products

4:00 pm Chair’s Closing Remarks

4:10 pm End of Conference